<DOC>
	<DOCNO>NCT01776684</DOCNO>
	<brief_summary>To detect resistance gene serially collect plasma DNA non-small cell lung cancer harbour EGFR activate mutation treat EGFR TKIs use castPCR method .</brief_summary>
	<brief_title>Evaluation EGFR TKI Resistance Mechanism Using Plasma DNA Analysis</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Histologically confirm NSCLC 2 . Aged old 20 year 3 . ECOG performance status 02 4 . Adequate hematological , renal , hepatic function 5 . Patients tumor harbor EGFR mutation ( del 19 L858R mutation ) 6 . Patient treat EGFR TKI ( gefitinib , erlotinib EGFR TKI ) 7 . At least one measurable disease 8 . Informed consent 1 . Active infection 2 . Active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>